Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 20;8(10):1115. doi: 10.3390/cells8101115

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

CPT1A amplification in prostate cancer across 16 publicly available studies. Data shown represents analysis of cBioportal database. A total of 3542 samples from 3313 patients across 16 studies were queried for CPT1A amplification (A): Graph shows frequency of CPT1A amplification across the studies. (B): Same data as in A, but reorganized according to PCa type: PA, prostate adenocarcinoma; NPC, neuroendocrine; CRPC, castration-resistant PCa. (C): Kaplan Meier curve showing overall survival for 484 patients. Red line shows cases with CPT1A amplification. Table shows the number of deceased cases and median months survival according to CPT1A amplification status.